Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-expressing”

224 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 224 results

Testing effectiveness (Phase 2)Looking for participantsNCT07474324
What this trial is testing

Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial

Who this might be right for
GC/GEJC
The First Affiliated Hospital with Nanjing Medical University 124
Early research (Phase 1)Active Not RecruitingNCT05311397
What this trial is testing

A166 in Patients With Advanced Solid Malignant Tumors

Who this might be right for
Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 120
Testing effectiveness (Phase 2)Looking for participantsNCT06026657
What this trial is testing

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8HER2-Negative Breast Carcinoma
Margaret Gatti-Mays 42
Early research (Phase 1)Ended earlyNCT02751528
What this trial is testing

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Who this might be right for
Cancer
NantBioScience, Inc. 3
Large-scale testing (Phase 3)Study completedNCT01007942
What this trial is testing

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
HER2/Neu Over-expressing Locally Advanced Breast CancerMetastatic Breast Cancer
Novartis Pharmaceuticals 569
Not applicableNot Yet RecruitingNCT07130344
What this trial is testing

PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer

Who this might be right for
Metastatic Breast CancerHER 2 Low-expressing Breast Cancer
Centre Paul Strauss 262
Early research (Phase 1)Study completedNCT00207012
What this trial is testing

MAD Refractory: Solid Tumor QD w/o Break

Who this might be right for
HER2 or EGFR Expressing Advanced Solid Malignancies
Bristol-Myers Squibb 45
Testing effectiveness (Phase 2)Ended earlyNCT01569412
What this trial is testing

Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors

Who this might be right for
Her2/Neu Positive Advanced Solid Tumors
Krankenhaus Nordwest 14
Testing effectiveness (Phase 2)Looking for participantsNCT06650332
What this trial is testing

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Who this might be right for
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Zhejiang Cancer Hospital 90
Testing effectiveness (Phase 2)Study completedNCT02129556
What this trial is testing

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer

Who this might be right for
Metastatic Breast Cancer
ETOP IBCSG Partners Foundation 58
Large-scale testing (Phase 3)Looking for participantsNCT06340568
What this trial is testing

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Who this might be right for
Endometrial Cancer
BioNTech SE 480
Testing effectiveness (Phase 2)Looking for participantsNCT07512583
What this trial is testing

Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 178
Early research (Phase 1)Study completedNCT00003002
What this trial is testing

HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer

Who this might be right for
Breast CancerLung CancerOvarian Cancer
University of Washington 60
Not applicableEnded earlyNCT02840110
What this trial is testing

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product

Who this might be right for
B Cell LymphomasMultiple MyelomaSolid Tumor+1 more
Cogent Biosciences, Inc. 22
Testing effectiveness (Phase 2)Looking for participantsNCT06155396
What this trial is testing

RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Who this might be right for
Cervical Cancer
RemeGen Co., Ltd. 116
Early research (Phase 1)UnknownNCT06154343
What this trial is testing

GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Who this might be right for
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
GeneQuantum Healthcare (Suzhou) Co., Ltd. 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225
What this trial is testing

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Who this might be right for
Breast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Early research (Phase 1)Study completedNCT00162929
What this trial is testing

Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe)

Who this might be right for
Metastatic Breast Cancer
Ontario Clinical Oncology Group (OCOG) 5
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06577376
What this trial is testing

A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaExpressing Human Epidermal Growth Factor Receptor-2 (HER-2)Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Early research (Phase 1)Study completedNCT00647114
What this trial is testing

Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)

Who this might be right for
Cancer
Merck Sharp & Dohme LLC 41
Load More Results
252